Literature DB >> 22411488

Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.

Teiichi Sugiura1, Katsuhiko Uesaka, Hideyuki Kanemoto, Takashi Mizuno, Keiko Sasaki, Hiroyoshi Furukawa, Kazuya Matsunaga, Atsuyuki Maeda.   

Abstract

OBJECTIVE: To evaluate the preoperative factors predictive of postoperative early recurrence in patients with resected pancreatic cancer focusing on the serum CA19-9 value.
METHODS: One hundred fifty-four patients undergoing surgical resection for pancreatic cancer were enrolled in this study. Univariate and multivariate analyses were performed to determine the predictors of early recurrence which was defined as relapse within 6 months after surgery.
RESULTS: On ROC curve analysis, the cutoff value of CA19-9 was determined to be 100 U/ml. Of 73 patients with CA19-9 value ≥ 100 U/ml, 39 (53 %) had early recurrence. In contrast, only 9 of 81 patients (11 %) with CA19-9 value < 100 U/ml developed a recurrence at an early period (p < 0.001). Multivariate analysis revealed that CA19-9 value ≥ 100 U/ml (odds ratio, 11.2) were significant predictors of early recurrence. The overall 3- and 5-year survival rates and median survival times were 47.3 %, 40.1 %, and 31 months in patients with CA19-9 value < 100 U/ml and 21.2 %, 9.4 %, and 16 months in patients with CA19-9 value ≥ 100 U/ml (p < 0.001).
CONCLUSIONS: A preoperative CA19-9 value ≥ 100 U/ml was a significant predictor of early recurrence and a poor prognosis after resection for pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22411488     DOI: 10.1007/s11605-012-1859-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  42 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma.

Authors:  Joshua G Barton; John P Bois; Michael G Sarr; Christina M Wood; Rui Qin; Kristine M Thomsen; Michael L Kendrick; Michael B Farnell
Journal:  J Gastrointest Surg       Date:  2009-09-09       Impact factor: 3.452

Review 3.  Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy.

Authors:  S P Povoski; M S Karpeh; K C Conlon; L H Blumgart; M F Brennan
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

4.  Prognostic value of CA 19-9 serum course in pancreatic cancer.

Authors:  F Safi; W Schlosser; S Falkenreck; H G Beger
Journal:  Hepatogastroenterology       Date:  1998 Jan-Feb

5.  Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

6.  Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.

Authors:  Adam C Berger; Ingrid M Meszoely; Eric A Ross; James C Watson; John P Hoffman
Journal:  Ann Surg Oncol       Date:  2004-06-14       Impact factor: 5.344

7.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

8.  Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography.

Authors:  Antonio Soriano; Antoni Castells; Carmen Ayuso; Juan Ramón Ayuso; Maria Teresa de Caralt; Maria Angels Ginès; Maria Isabel Real; Rosa Gilabert; Llorenç Quintó; Antoni Trilla; Faust Feu; Xavier Montanyà; Laureano Fernández-Cruz; Salvador Navarro
Journal:  Am J Gastroenterol       Date:  2004-03       Impact factor: 10.864

9.  Margin clearance and outcome in resected pancreatic cancer.

Authors:  David K Chang; Amber L Johns; Neil D Merrett; Anthony J Gill; Emily K Colvin; Christopher J Scarlett; Nam Q Nguyen; Rupert W L Leong; Peter H Cosman; Mark I Kelly; Robert L Sutherland; Susan M Henshall; James G Kench; Andrew V Biankin
Journal:  J Clin Oncol       Date:  2009-04-27       Impact factor: 44.544

10.  Prognostic factors after resection of pancreatic cancer.

Authors:  Michio Ueda; Itaru Endo; Masayuki Nakashima; Yuta Minami; Kazuhisa Takeda; Kenichi Matsuo; Yasuhiko Nagano; Kuniya Tanaka; Yasushi Ichikawa; Shinji Togo; Chikara Kunisaki; Hiroshi Shimada
Journal:  World J Surg       Date:  2009-01       Impact factor: 3.352

View more
  45 in total

1.  Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.

Authors:  Ching-Wei D Tzeng; Aparna Balachandran; Mediha Ahmad; Jeffrey E Lee; Sunil Krishnan; Huamin Wang; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Peter W T Pisters; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

Review 2.  Challenges of Pancreatic Cancer.

Authors:  Julien Dimastromatteo; Jacob L Houghton; Jason S Lewis; Kimberly A Kelly
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

Review 3.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

4.  Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China.

Authors:  Weikang Liu; Bingjun Tang; Feng Wang; Chang Qu; Hao Hu; Yan Zhuang; Hongqiao Gao; Xuehai Xie; Xiaodong Tian; Yinmo Yang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

5.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-03-23       Impact factor: 12.969

6.  Multimodality treatment of recurrent pancreatic cancer: Mith or reality?

Authors:  Cosimo Sperti; Lucia Moletta; Stefano Merigliano
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

7.  Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.

Authors:  Steve Walston; Joseph Salloum; Carmine Grieco; Evan Wuthrick; Dayssy A Diaz; Christian Barney; Andrei Manilchuk; Carl Schmidt; Mary Dillhoff; Timothy M Pawlik; Terence M Williams
Journal:  Am J Clin Oncol       Date:  2018-12       Impact factor: 2.339

8.  Predictors of postoperative early recurrence of extrahepatic bile duct cancer.

Authors:  Masayuki Akita; Tetsuo Ajiki; Kimihiko Ueno; Daisuke Tsugawa; Yu Hashimoto; Motofumi Tanaka; Masahiro Kido; Hirochika Toyama; Takumi Fukumoto
Journal:  Surg Today       Date:  2019-09-23       Impact factor: 2.549

9.  Risk factor of surgical site infection after pancreaticoduodenectomy.

Authors:  Teiichi Sugiura; Katsuhiko Uesaka; Norio Ohmagari; Hideyuki Kanemoto; Takashi Mizuno
Journal:  World J Surg       Date:  2012-12       Impact factor: 3.352

10.  Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.

Authors:  Riccardo Piagnerelli; Daniele Marrelli; Giandomenico Roviello; Francesco Ferrara; Giulio Di Mare; Costantino Voglino; Roberto Petrioli; Mario Marini; Raffaele Macchiarelli; Franco Roviello
Journal:  Tumour Biol       Date:  2015-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.